| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8217012 | International Journal of Radiation Oncology*Biology*Physics | 2015 | 10 Pages |
Abstract
Neoadjuvant chemoradiation therapy between 45 and 54Â Gy was associated with superior survival in comparison with doses above and below this threshold. Although this conclusion is limited by selection bias, clear candidates for trimodality therapy do not seem to achieve additional benefit with dose escalation.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
David J. MD, MPH, Mary Jo MD, Christopher W. MD, Michael J. MD, Matthew MD,